MedTrace Logo

A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy

NCT07434050 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-04-13

No results posted yet for this study

Summary

The aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA receiving PAP

Conditions

  • OSA - Obstructive Sleep Apnea
  • Obesity

Interventions

DRUG

XW003 injection

subcutaneous injection

DRUG

placebo with matching volume

subcutaneous injection

Sponsors & Collaborators

  • Hangzhou Sciwind Biosciences Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Qingyun Li, Dr · Ruijin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-02
Primary Completion
2028-06-19
Completion
2028-06-19

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07434050 on ClinicalTrials.gov